General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1 — At a Glance
The company generated ₹102 cr in revenue for FY26, an increase from ₹100 cr the prior year. However, operating profit swung into red territory at -₹24 cr, driven by a -24% operating margin. Net profit hit -₹29 cr (loss).
A rights issue in May 2026 raised ₹70 cr at ₹40 per share (155% subscribed). Shares issued rose from 2.8 cr to 9.3 cr, instantly diluting the equity base by 230%.
Total debt stands at ₹113 cr against a ₹1,067 cr market cap. Interest coverage has collapsed into negative territory. The balance sheet now shows ₹278 cr in total liabilities against ₹278 cr in assets — a 1:1 levering with minimal buffer.
Inventories are ₹56 cr; receivables ₹31 cr; cash ₹5 cr. The company is burning cash to sustain operations and expanding headcount and asset base.
What happens when a CRDMO with zero near-term profitability runs out of fresh capital?
2 — Introduction
Innovassynth Technologies (ITIL) is a chemistry-focused contract research, development, and manufacturing organization (CRDMO) incorporated in 2008 and positioned in the specialty chemicals and pharmaceutical intermediates space.
The company operates across three verticals: pharmaceutical intermediates, oligonucleotide building blocks, and specialty chemicals. It serves global life sciences and advanced materials customers with custom synthesis, process development, scale-up, and commercial manufacturing.
In 2022, the business transitioned to profitability with a ₹22 cr net profit, backed by ₹203 cr revenue. Since then, margins have eroded and losses have resumed. FY24 and FY25 posted net losses of ₹1 cr and ₹1 cr respectively before ballooning to -₹29 cr in FY26.
A postal ballot in March 2026 approved increased borrowing limits. The subsequent rights issue was meant to address this burn.
The company’s Khopoli facility has been augmented with capex aimed at capacity expansion for oligonucleotide and specialty chemical manufacturing.
3 — Business Model: WTF Do They Even Do?
Innovassynth is a CRDMO — a middleman between pharmaceutical discovery firms and final manufacturing. It doesn’t invent drugs. It makes the intermediate chemicals that go into them, or builds the building blocks (nucleosides, amidites) that RNA/DNA therapy companies need.
The oligonucleotide vertical is the crown jewel: nucleosides and amidites are the monomeric units of DNA and RNA, used in mRNA vaccines, gene therapy, and RNA therapeutics. As that market expands (it has), demand for oligos compounds.
The specialty chemicals vertical serves polyolefins (plastics), organometallic catalysts (used in fine chemistry), and semiconductor materials. This is a low-margin, high-volume game — competitive, price-sensitive, and vulnerable to cost shocks.
The pharmaceutical intermediates vertical is the legacy play: custom synthesis for drug discovery and manufacturing. Margins are thin, customers are global (so FX risk bites), and capacity utilization is the bottleneck.
Revenue mix in FY25 was 99% product sales, 1% other income. That makes the business a one-trick: if synthesis demand drops or margins compress, there’s no buffer.
The CRDMO model is asset-heavy and capital-hungry. Khopoli is now saddled with ₹130 cr in net block (fixed assets), requiring continuous investment and debt service.
4 — Financials Overview
Figures are consolidated, in ₹ crore.
| Metric | FY26 | FY25 | FY24 | YoY Change |
|---|---|---|---|---|
| Revenue | 102.35 | 102.35 | 102.35 | — |
| EBITDA | -16 | — | — | — |
| Operating Profit | -24 | — | — | — |
| PAT (Net Profit) | -29 | -1 | -1 | -2,800% |
| EPS (Annualised) | -3.10 | — | — | — |
FY26 Quarterly Trajectory:
- Q1 (Jun 25): Revenue ₹0, PAT ₹0 (no data reported or minimal operations).
- Q2 (Sep 25): Revenue ₹17 cr, PAT -₹14 cr.
- Q3 (Dec 25): Revenue ₹22 cr, PAT -₹8 cr.
- Q4 (Mar 26): Revenue ₹51 cr, PAT ₹12 cr.
The company went from cumulative losses of ₹22 cr in the first three quarters to a sole profitable quarter in Q4. That single quarter of ₹12 cr profit offset most of the damage, but not all. The full-year loss of ₹29 cr includes the rights issue proceeds (which inflate the balance sheet) but not the dilution’s ongoing drag on earnings per share.
Q4 saw a 23% OPM — a rare bright spot. Q2 posted -64% OPM. Volatility is extreme.
Interest & Debt Service:
Interest expense for FY26 was ₹7.23 cr on ₹113 cr of gross debt. The effective interest rate is ~6.4%, reasonable for a loss-making company in India but unsustainable given negative EBITDA.
5 — Market Expectations & Historical Multiples
This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.
| Metric | Current | FY25 | FY24 | FY23 | Peer Median |
|---|---|---|---|---|---|
| P/E | — | — | — | — | 20.1x |
| EV/EBITDA | — | — | — | — | 8.5x |
| Price-to-Book | 11.3x | 14.1x | — | — | 1.47x |
| ROE | -41% | -21% | -1% | -1% | 6.6% |
| ROCE | -25% | -1% | -1% | -1% | 8.5% |
(Current price: ₹114.89; market cap ₹1,067 cr; referenced prices are not live.)
The market trades the equity at 11.3x book value — a sizable premium to the peer median of 1.47x. This premium reflects market expectations for a turnaround, not current fundamentals.
P/E is unmeaningful (the company is loss-making); the market appears to be pricing optionality: a bet that oligonucleotide demand will drive volume and margins higher within the decade.
ROE of -41% signals that the equity base is destroying itself faster than it can earn. ROCE of -25% means capital employed in operations is not generating returns; it is being consumed.
The peer set (SRF, Deepak Fertilizers, GNFC, Tanfac, GHCL) trade at P/Es of 9x to 70x with positive ROCE (1% to 24%). Innovassynth’s negative ROE and ROCE are outliers in this cohort.
6 — What’s Cooking
Rights Issue (May 2026): The company raised ₹70 cr by issuing 1.74 cr shares at ₹40 per share. Subscription was 155%, suggesting investor interest despite losses. Share count expanded from 2.8 cr to 9.3 cr — a 232% dilution. The proceeds are being deployed into capex and working capital.
Capex on Oligonucleotide Expansion: The net block grew from ₹0 to ₹130 cr in FY26 alone. Capital work in progress stands at ₹4 cr. The company is building manufacturing capacity for oligos and specialty chemicals at Khopoli.
Q4 Profitability: The sole profitable quarter — Q4 FY26 with ₹12 cr net profit and a 23% OPM — suggests the asset base is beginning to be utilised. Revenue jumped to ₹51 cr in Q4 versus ₹22 cr in Q3.
Inventory Buildup: Inventory rose to ₹56 cr, a 230% surge year-on-year. This could signal precautionary stocking ahead of demand or operational inefficiency in converting stock to sales. Inventory turnover has frozen.
Cash Burn: Operating cash flow was -₹39 cr in FY26. The company burned cash to fund operations and capex. The financing activity generated ₹29 cr (mostly the rights issue proceeds). Without the capital raise, cash would have deteriorated by ₹48 cr.
Debt Balloons to ₹113 cr: Borrowings increased from ₹4 cr to ₹113 cr. This includes the rights-issue-linked debt or vendor financing to fund capex. Debt-to-equity has jumped to 1.19x from 0.16x.
7 — Balance Sheet: The Asset Base Materializes
| Item | FY26 | FY25 | FY24 |
|---|---|---|---|
| Total Assets | 278 | 50 | 39 |
| Equity Capital | 75 | 28 | 24 |
| Reserves | 19 | 15 | 9 |
| Borrowings | 113 | 4 | 4 |
| Other Liabilities | 71 | 2 | 2 |
The balance sheet swelled five-fold in a single year. Assets = Liabilities = ₹278 cr (reconciles).
The breakdown is stark:
- Fixed assets (net block) jumped from ₹0 to ₹130 cr — the oligonucleotide capex is now concrete. Depreciation will be ₹8 cr annually, a drag on profitability for years.
- Current assets (Other Assets, Receivables, Inventory, Cash) total ₹234 cr, but net cash is negative: ₹5 cr in cash against ₹31 cr receivables and ₹56 cr inventory leaves a working capital deficit of ₹82 cr after paying ₹71 cr in current liabilities.
- Reserves (accumulated loss buffer) have barely grown to ₹19 cr despite the rights raise, showing that losses are still eating into equity.
The company has swapped equity (₹70 cr from rights) and debt (₹109 cr increase) for assets and working capital. It is now a leveraged bet on oligo utilization rates and margin recovery.
8 — Cash Flow: Sab Number Game Hai
| Year | Operating | Investing | Financing | Net |
|---|---|---|---|---|
| FY26 | -39 | -9 | 29 | -19 |
| FY25 | -1 | 0 | 1 | 0 |
| FY24 | -0 | 0 | 0 | -0 |
The story is brutal: operating cash flow is deeply negative, burning ₹39 cr to fund day-to-day operations and meet payables.
Investing cash flow of -₹9 cr is capex (low relative to the ₹130 cr asset addition, so much capex was likely financed directly through debt or payables inflation).
Financing activity of ₹29 cr was the rights issue proceeds — the only thing keeping the company afloat.
Free cash flow for FY26 was -₹45 cr. Without external capital, the company would have depleted its balance sheet in months.
The cash conversion cycle is broken. Debtor days are 112, inventory days likely exceed 200, and payables days are 376 — the company is floating on vendor credit and not generating cash from core operations.
9 — Ratios: Sexy or Stressy?
| Ratio | FY26 |
|---|---|
| ROE | -41% |
| ROCE | -25% |
| P/E | — |
| Net Profit Margin | -27% |
| Debt-to-Equity | 1.19 |
ROE of -41%: The equity base (₹94 cr post-rights issue) is shrinking, not growing. Shareholder capital is being destroyed at 41 cents per rupee per year.
ROCE of -25%: Capital employed (equity + debt = ₹207 cr) is not generating returns; it is consuming value. A company with negative ROCE in a capital-heavy business is in a race against time.
Net Margin of -27%: Out of every ₹100 in sales, the company loses ₹27. Scaling revenue won’t help if margins don’t flip. This is a structure problem.
Debt-to-Equity of 1.19: Debt exceeds equity after the rights raise. One default by a major customer or a prolonged demand drought would breach debt covenants.
10 — P&L Breakdown: Show Me the Money
| Year | Revenue | EBITDA | PAT |
|---|---|---|---|
| FY26 | 102.35 | -16 | -29 |
| FY25 | 102.35 | — | -1 |
| FY24 | 102.35 | — | -1 |
The trajectory is sideways revenue with worsening losses.
FY26 EBITDA turned negative at -₹16 cr (operating loss of -₹24 cr less depreciation of ₹8 cr). This means the core business — before interest and tax — is unprofitable.
The PAT loss of -₹29 cr includes a ₹11 cr tax benefit (loss offset), so the pre-tax loss was -₹40 cr.
The only bright spot is Q4, which posted operating profit of ₹6 cr and net profit of ₹12 cr. But four quarters of similar Q4 performance would yield ₹48 cr profit — still not enough to cover debt service and capex depreciation.
11 — Peer Comparison
| Company | Revenue (FY26) | PAT (FY26) | P/E |
|---|---|---|---|
| SRF | 15,787 cr | 1,903 cr | 42.7x |
| Deepak Fertilis. | 11,506 cr | 737 cr | 26.6x |
| GNFC | 7,773 cr | 808 cr | 9.2x |
| GHCL | 3,064 cr | 456 cr | 8.7x |
| Tanfac Inds. | 711 cr | 70 cr | 57.4x |
| Innovassynth | 102 cr | -29 cr | — |
| Peer Median | 7,340 cr | 480 cr | 20.1x |
Innovassynth is three to four orders of magnitude smaller than the peer set. It is loss-making while peers are profitable. Revenue scale is ₹102 cr against a median of ₹7,340 cr — a 72x gap.
The scale gap means the company has no pricing power, limited customer diversification, and weak bargaining leverage with suppliers. Its specialty chemical and oligo volumes are drops in an ocean dominated by SRF, GNFC, and their ilk.
Peer P/Es range from 8.7x (GHCL) to 57.4x (Tanfac, a niche specialty player). Innovassynth’s loss-making status puts it outside the P/E comparison. The company has to prove profitability before multiple re-rating is meaningful.
12 — Miscellaneous: Shareholding & Promoters
| Holder | May 2026 |
|---|---|
| Promoters | 75.04% |
| FIIs | 1.13% |
| DIIs | 1.24% |
| Public | 22.60% |
Viren Rajan Raheja and Akshay Rajan Raheja (individual promoters) hold 50.8% combined. Matsyagandha Investments Private Limited (group entity) holds 7.18%. Other group entities (R Raheja Investments, Globus Stores, Bloomingdale Investments) hold a further 9.85%. Total group control is robust at 75%.
The Raheja family assembled this company and continues to back it through the loss cycle. The ₹70 cr rights issue was almost entirely taken up by promoters, signaling conviction in a turnaround.
However, the rights issue also tripled the share count — a warning signal that promoters are willing to dilute themselves to buy time. This works only if the new capex generates returns within two to three years.
DIIs hold 1.24%, a trivial position. FIIs at 1.13% suggest minimal global institutional interest. The public float of 22.6% is illiquid.
13 — Corporate Governance: Angels or Devils?
Auditors shifted from MSKA & Associates (retired FY22) to P G Bhagwat LLP. No audit qualifications are reported.
The board includes independent directors (governance structure is statutory). Related-party transactions have been disclosed and remain within limits.
In May 2026, the company incurred two regulatory fines: ₹10,000 from BSE for delayed board meeting intimation and ₹11,800 for SEBI LODR non-compliances. Both were paid. These are minor — compliance lapses, not fraud — but flag weak administrative controls.
In January 2025, CARE Ratings withdrew the rating on the company’s bank facilities, citing that the company is not cooperating with the rating agency. The company was later dissolved (without winding up) by the NCLT Mumbai Bench on November 14, 2025 (per the credit rating press release dated April 13, 2026), but it continues to operate and file results.
This is a major red flag. A dissolution order suggests the company may have faced insolvency proceedings or restructuring intervention by the NCLT. The current FY26 results (filed May 2026) post-date the NCLT order, suggesting the order was either overturned on appeal or the company is operating under NCLT supervision.
14 — Industry Roast & Macro Context
The CRDMO space in India is fragmented. Innovassynth competes against Syngene, Laurus Labs, Evonik, and dozens of smaller regional players.
The oligonucleotide vertical is the growth story. mRNA vaccine demand (Moderna, BioNTech, Indian vaccine makers) has created a tailwind for nucleoside and amidite suppliers. This is real. Innovassynth’s capex is betting on exactly this demand curve. If oligo volumes scale, the company’s fixed assets will be optimally used and margins will explode.
But the downside is brutal. Oligo manufacturing is commoditizing. China and Europe are also investing in capacity. If prices compress before Innovassynth hits full utilization, the capex becomes a stranded asset. The company would carry ₹130 cr in fixed assets generating negative returns — a sinking ship.
Pharmaceutical intermediates remain low-margin. Pricing power is nonexistent. Customers (big pharma R&D labs and smaller contract manufacturers) are sticky but price-sensitive. Revenue per unit of capex is low. This vertical alone won’t sustain the business.
Specialty chemicals are cyclical. Polyolefin and catalyst demand ride the broader manufacturing cycle. A global slowdown would crater volumes immediately.
Geopolitical risk: If the US or EU restricts Chinese oligo imports and mandates domestic or India-friendly sourcing, Innovassynth could become a preferred partner. Conversely, if China opens capacity and undercuts on price, Innovassynth is squeezed.
15 — EduInvesting Verdict
| Strengths | Weaknesses |
|---|---|
| Oligonucleotide demand tailwinds; ₹130 cr capex now in place | Revenue flat at ₹102 cr; operating losses widening |
| Q4 FY26 profitability (₹12 cr) signals utilization pickup | -₹39 cr operating cash flow; heavy debt load (₹113 cr) |
| Promoter conviction (75% holding; full rights issue uptake) | P/B ratio 11.3x vs peer 1.47x; ROE -41%, ROCE -25% |
| Niche CRDMO in a growing sector | NCLT dissolution order (November 2025) — restructuring shadow |
| Opportunities | Threats |
|---|---|
| Oligo demand from mRNA therapeutics scales over 5 yrs | Commodity oligo pricing pressure; China capacity ramp |
| Pharma intermediates scale if R&D outsourcing to India grows | Debt covenant breach if volumes don’t materialize; equity wipeout risk |
| Specialty chemicals stable if industrial demand holds | FX headwinds (global customers = rupee exposure); vendor credit drying up |
The company has built a fortress of capex in the hope that oligonucleotide demand will make it hum. Q4 FY26 offered the first proof of concept. But one quarter of profitability does not redeem a trajectory of losses, negative cash flow, and leverage that rivals the asset base itself.
The balance sheet has nothing to hide and everything yet to prove.